

PRESS RELEASE

Lund - 25 January 2012



Directed new share issue by Hansa Medical AB (publ) completed

On January 9 2012 a Hansa Medical AB (publ) Extraordinary Meeting resolved to follow the proposal of the Board of Directors of Hansa Medical to carry out a directed share issue to NXT2B, the privately owned venture capital firm of Bengt Ågerup. The share issue comprising 5,000,001 shares at the share price SEK 5.50 is now completed and the share issue has provided SEK 27.5 million to Hansa Medical AB (publ). The share issue has increased the company's share capital by SEK 25,000,005 and today amounts SEK 92,605,725. The total number of outstanding shares is 18,521,145 after the share emission and NXT2B holds 27.0 percent of the outstanding shares.

For further information, please contact:

Emanuel Björne, CEO Hansa Medical AB

Mobile: +46 707 17 54 77

E-mail: emanuel.bjorne@hansamedical.com

ABOUT HANSA MEDICAL

Hansa Medical is a biotechnology research and development company focused on the treatment and diagnosis of inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoS and HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company's Certified Adviser.

Hansa Medical AB
P.O. Box 785
SE-220 07 Lund
Telephone +46 46 16 56 70
Fax +46 46 12 77 75
info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Scheelevägen 22
Lund